

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.

Learn more: [PMC Disclaimer](#) | [PMC Copyright Notice](#)



International Journal of  
*Molecular Sciences*



*Int J Mol Sci.* 2023 Mar 8;24(6):5181. doi: [10.3390/ijms24065181](https://doi.org/10.3390/ijms24065181)

# The Tissue Response to Hypoxia: How Therapeutic Carbon Dioxide Moves the Response toward Homeostasis and Away from Instability

[Richard J Rivers](#)<sup>1,\*</sup>, [Cynthia J Meininger](#)<sup>2</sup>

Editor: Lih Kuo

[Author information](#) [Article notes](#) [Copyright and License information](#)

PMCID: PMC10048965 PMID: [36982254](#)

## Abstract

---

Sustained tissue hypoxia is associated with many pathophysiological conditions, including chronic inflammation, chronic wounds, slow-healing fractures, microvascular complications of diabetes, and metastatic spread of tumors. This extended deficiency of oxygen

(O<sub>2</sub>) in the tissue sets creates a microenvironment that supports inflammation and initiates cell survival paradigms. Elevating tissue carbon dioxide levels (CO<sub>2</sub>) pushes the tissue environment toward “thrive mode,” bringing increased blood flow, added O<sub>2</sub>, reduced inflammation, and enhanced angiogenesis. This review presents the science supporting the clinical benefits observed with the administration of therapeutic CO<sub>2</sub>. It also presents the current knowledge regarding the cellular and molecular mechanisms responsible for the biological effects of CO<sub>2</sub> therapy. The most notable findings of the review include (a) CO<sub>2</sub> activates angiogenesis not mediated by hypoxia-inducible factor 1a, (b) CO<sub>2</sub> is strongly anti-inflammatory, (c) CO<sub>2</sub> inhibits tumor growth and metastasis, and (d) CO<sub>2</sub> can stimulate the same pathways as exercise and thereby, acts as a critical mediator in the biological response of skeletal muscle to tissue hypoxia.

**Keywords:** transdermal carbon dioxide, hypoxia, hypoxia-inducible factor-1a, angiogenesis, diabetes, peripheral vascular disease, exercise, CO<sub>2</sub> therapy, carboxy therapy

## 1. Introduction

---

Oxygen (O<sub>2</sub>) is carried in the blood and delivered to cells in tissues. O<sub>2</sub> is necessary for normal cell respiration, serving as an electron acceptor in the electron transport system. Carbon dioxide (CO<sub>2</sub>) is produced as a byproduct of cellular respiration. Normal tissue function requires a balance between O<sub>2</sub> delivery and CO<sub>2</sub> removal. When blood flow is too low or when tissue O<sub>2</sub> demand exceeds delivery (such as during exercise), tissue hypoxia ensues, and metabolic byproducts, including CO<sub>2</sub>, build up in the tissues [1,2]. CO<sub>2</sub> causes dilation of blood vessels, bringing about greater blood flow, increased O<sub>2</sub> delivery, and removal of vasodilatory metabolites. The resulting reduction in vasodilatory signals brings blood flow

back to homeostatic levels. This metabolic regulation of blood flow guarantees an adequate supply of blood to the tissues and microvascular stability. In this way, the local supply of O<sub>2</sub> by the circulation is matched to the local demand by the tissues.

Cardiovascular and microvascular diseases can be caused by the chronic disruption of normal blood flow that makes previously healthy tissues cascade into a severe and, at times, permanent pathological condition. The condition caused by sustained hypoxia results in a slowed metabolism that is dependent on glycolytic pathways and a chronic inflammatory state that is perpetuated by an increase in hypoxia-inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ) production. Multiple transcriptional responses to HIF-1 $\alpha$  promote a survival response in cells, preventing cell death in response to continued hypoxia [3]. Beyond cell survival, a major function of HIF-1 $\alpha$  is the transcriptional activation of genes involved in new blood vessel growth. This neovascularization improves blood flow to supply more O<sub>2</sub> to the tissue and reverse the hypoxia.

In contrast with the survival mode induced by severe or chronic hypoxia, the limited or transient hypoxia brought about by increased metabolic demand in tissues results in an acute decrease in ATP stores that is sensed by cells via the action of adenosine monophosphate-activated protein kinase (AMPK) [4]. AMPK senses cellular energy status by monitoring the ATP:AMP ratio. When this ratio is decreased, AMPK restores energy balance by inhibiting anabolic reactions that consume ATP and promoting catabolic processes that generate ATP. AMPK activation in vascular endothelial cells results in vasodilation and new blood vessel growth to increase blood flow and oxygen delivery to the tissue, thus restoring normal tissue function [4].

CO<sub>2</sub> levels in the tissue rise immediately in response to increased

metabolic demand. Elevated tissue CO<sub>2</sub> acts as a sensitive trigger for cellular responses to hypoxia, modulating biological signaling pathways (e.g., HIF-1α and AMPK) to restore normal tissue function and homeostasis. This review presents data highlighting the potential use of CO<sub>2</sub> as a therapeutic approach to tissue hypoxia to promote tissue repair, reduce inflammation, reverse the pathophysiological effects of hyperglycemia, and enhance the efficacy of cancer therapy. Moreover, it summarizes the status of knowledge of the cellular and molecular mechanisms underlying these beneficial effects of therapeutic CO<sub>2</sub> delivery.

## 2. Therapeutic Effects of Carbon Dioxide

---

The use of CO<sub>2</sub> as a therapeutic treatment for various ailments dates back hundreds of years when people visited and built cities around the hot springs of Europe. The medicinal effects of the waters found in hot springs have been attributed to dissolved CO<sub>2</sub> in the form of carbonic acid [5]. There are now many more methods for using therapeutic CO<sub>2</sub>. Such treatment regimens used today include carbonated water (i.e., baths) (CB) [6], CO<sub>2</sub> gas applied to the skin (transdermal [TD]) [7,8], intra-arterial infusions of carbonated solutions into tumors (IA) [9], intraperitoneal injection of CO<sub>2</sub> (IP) [10], inhaled CO<sub>2</sub> or hypercarbia (IH) [11], carbonated paste or gel (CG) [12], and subcutaneous microinjections of CO<sub>2</sub> (SQ) [13]. In all these therapeutic applications, except for SQ, CO<sub>2</sub> is applied for 10–20 min. Treatment schedules vary from 1–3 days apart, and the number of treatments varies from one (SQ, IA, and IP) to 4–20 for the other therapies. Dosing studies are rare, but one study showed that treatments must be applied every 2–3 days to be effective in healing fractures [14]. No studies have noted any adverse side effects or complications from CO<sub>2</sub> therapy except for SQ, where bleeding or bruising can occur. It should be noted, however, that CO<sub>2</sub> is anti-inflammatory, so treating an infected wound should be

done with caution.

Modern studies have shown that therapeutic CO<sub>2</sub> applied to wounds, tumors, and through the skin to underlying tissues has dramatic and long-lasting effects on inflammation, oxygenation, angiogenesis, and healing. Clinical and experimental findings using therapeutic CO<sub>2</sub> are summarized here.

## 2.1. Accelerated Wound and Fracture Healing

There are now several studies investigating the effects of therapeutic CO<sub>2</sub> on wounds and fractures. Studies in rats treated with TD CO<sub>2</sub> demonstrated increased survival of skin flaps due to increased blood flow and greater capillary density [15]. This correlated with increased gene expression of basic fibroblast growth factor and vascular endothelial growth factor (VEGF) but a paradoxical decrease in HIF-1 $\alpha$ . In a retrospective study of topical TD CO<sub>2</sub> treatment of 86 human patients with chronic wounds and 17 patients with acute wounds, all patients had resolution of their wounds [16]. The CO<sub>2</sub> gas was able to penetrate the granulation tissue of the wound bed to support/accelerate healing while improving the microcirculation and reducing the incidence of infection. Humans with diabetes often have chronic wounds that do not heal and eventually lead to the need for amputation. A double-blind study showed that TD CO<sub>2</sub> therapy would heal these long-standing wounds [17]. By the end of the study, 66% of the CO<sub>2</sub>-treated wounds had healed completely, and wound volume decreased by 99%. In the control group, none of the wounds completely healed.

Clinicians have very limited options to biologically improve bone fracture repair. Blood flow and angiogenesis at the site of a fracture are critical components of fracture repair. When rats with long bone

fractures were treated with TD CO<sub>2</sub>, fracture union was accelerated [14,18]. For example, fracture union was evident at week 3 in 86% of animals in the treated group compared with 36% in the control group [18]. Increased blood flow and greater capillary density at the fracture site were accompanied by elevated expression of chondrogenic and osteogenic genes resulting in early production of collagen and cartilage. Increased angiogenesis and blood flow induced by the TD CO<sub>2</sub> treatment likely promoted blood vessel invasion and transformation of the avascular cartilaginous matrix into vascularized osseous tissue.

In the Phase I clinical trial involving 19 human patients with fractures of the lower extremities, CO<sub>2</sub> was applied to the affected limb, and blood flow was measured in both limbs [19]. This TD CO<sub>2</sub> therapy promoted an approximately two-fold increase in blood flow in the fractured limbs. As a result of the increase in blood flow, enhanced local oxygenation likely contributed to tissue healing. Importantly, no adverse events, including hypercapnia, were noted in these patients, supporting the validity of continuing assessments of CO<sub>2</sub> therapy in additional clinical trials. Increased blood flow and greater O<sub>2</sub> delivery suggest that CO<sub>2</sub> therapy will be beneficial for the treatment of fractures in humans, including fractures in patients with the ischemic disease or diabetes mellitus, in smokers, and in those individuals with avascular nonunion [19].

## 2.2. Increased Blood Flow to Ischemic Limbs

Treatment of ischemia in limbs due to peripheral vascular disease is very challenging and commonly includes multiple surgeries and loss of toes and/or limbs. Experiments in mice and rats with unilateral hindlimb ischemia showed that CB and TD CO<sub>2</sub> therapy induced elevated levels of VEGF in addition to activating the nitric oxide-cyclic guanosine-monophosphate (NO-cGMP) system to increase

blood flow to the limb [20,21]. Treatment increased capillary density and collateral vessel formation in the ischemic limb as well as the number of endothelial cell progenitors in the circulation [21].

TD CO<sub>2</sub> improved blood flow and preserved tissue in humans with peripheral vascular disease [22,23,24]. In a study of patients with ischemic ulceration due to severe stenosis or vascular occlusion, 83% of limbs were salvaged with CO<sub>2</sub> therapy, thus reducing the need for amputation in patients with critical limb ischemia (CLI) [22]. Transcutaneous CO<sub>2</sub> acts as a vasodilator, opening nonfunctioning capillaries to enhance the O<sub>2</sub> diffusion area (CLI) [23]. Increases in tissue CO<sub>2</sub> concentration affect both blood flow (tissue perfusion) and the capacity of hemoglobin to release O<sub>2</sub> (the shift in the O<sub>2</sub> dissociation curve known as the Bohr effect).

Therapeutic TD CO<sub>2</sub> reduced claudication (pain caused by reduced blood flow to the legs) and increased pain-free and total walking distance by 66% and 73%, respectively, in patients with critical limb ischemia [24]. Importantly, these effects were maintained for 12 months after cessation of therapy.

### 2.3. Greater Blood Flow and Vascularization in Diabetes

Diabetes is a major risk factor for the development of peripheral vascular disease. In a rat model of diabetes mellitus with hindlimb ischemia, TD therapy resulted in a two-fold increase in peak and mean blood flow in hindlimb skeletal muscle as well as a two-fold increase in the number of small blood vessels in skeletal muscle sections (CLI) [6]. Both the structure and function of the microvasculature of skeletal muscle are known to be altered in diabetes. Hyperglycemia, resulting from poorly controlled diabetes, reduces skeletal muscle capillarization via an imbalance in pro- and anti-angiogenic factors [25]. TD CO<sub>2</sub> therapy in rats with

streptozotocin-(STZ-)-induced diabetes, a model of type I diabetes, increased blood flow in the soleus muscle, attenuated capillary rarefaction and restored the balance of angiogenic growth factors [26].

In addition to causing changes in vascular architecture and density in skeletal muscle, hyperglycemia can reduce oxidative capacity, the measure of a muscle's maximal capacity to use O<sub>2</sub>, by reducing mitochondrial enzymatic activity and biogenesis [27]. The activity of citrate synthase (CS), a key mitochondrial enzyme in the tricarboxylic acid cycle, is used as an indicator of the oxidative capacity of skeletal muscle. CS activity in the soleus muscle was reduced in STZ-induced diabetic rats compared to nondiabetic rats, but cutaneous CO<sub>2</sub> treatment increased CS activity in diabetic rats compared to diabetic rats without treatment and brought CS activity up to levels measured in nondiabetic control rats [27]. The cytochrome c oxidase (COX) complex catalyzes the final step in the mitochondrial electron transfer chain and is regarded as one of the major regulation sites for mitochondrial function and, thus, oxidative phosphorylation. Hyperglycemia reduced levels of COX subunit 4, essential for the assembly and respiratory function of the COX complex, while TD CO<sub>2</sub> attenuated this effect [27].

Oxidative capacity is regulated by peroxisome proliferator-activated receptor-gamma co-activator-1 alpha (PGC-1α), and low oxidative capacity in diabetes correlates with decreased PGC-1α expression. CO<sub>2</sub> therapy increases NO production in skeletal muscle via an increase in blood flow. NO can increase PGC-1α protein expression via activation of cGMP and promotes mitochondrial biogenesis and function. Of note, the application of TD CO<sub>2</sub> not only increased oxidative capacity in skeletal muscle, but CO<sub>2</sub> also improved hyperglycemia via an increase in glucose metabolism mediated by increased PGC-1α expression [27].

## 2.4. Improved Skeletal Muscle Function and Healing

Endurance (aerobic) exercise increases skeletal muscle oxidative capacity, mitochondrial biogenesis, and muscle fiber-type switching (via an increase in PGC-1 $\alpha$  expression) while also stimulating angiogenesis (via upregulation of VEGF). This links the regulation of the consumption of O<sub>2</sub> by mitochondria to the delivery of O<sub>2</sub> and nutrients by the vasculature. Elevating tissue CO<sub>2</sub> can cause a skeletal muscle to respond as though it has been exercising. For example, compared to nontreated rats, skeletal muscle in rats treated with CO<sub>2</sub> displays an increase in mitochondria number as well as elevations in the expression of PGC-1 $\alpha$ , VEGF, and sirtuin 1 (SIRT1) (TD) [28]. SIRT1 supports mitochondrial biogenesis and muscle fiber-type changes to increase ATP production and improve muscle performance. These data are consistent with the greater endurance [29] and more efficient muscle activity [30] noted in humans (CB) and rats (TD), respectively, following CO<sub>2</sub> therapy.

TD application of CO<sub>2</sub> may have therapeutic potential for muscle regeneration and strength recovery following injury. In a study of rats with a skeletal muscle injury, injured muscle fibers were completely repaired at week six in the CO<sub>2</sub>-treated group but only partially repaired in the untreated group [31]. Expression levels of the muscle-specific transcription factors MyoD and myogenin (involved in differentiation of myoblasts into myotubes) were increased at week two after injury in the CO<sub>2</sub>-treated group (signaling an acceleration of the regeneration process and differentiation of muscle cells), and significantly more capillaries were seen four weeks after injury. Angiogenesis is a prerequisite for morphological and functional healing, leading to the rebuilding of damaged vessels, re-establishment of blood flow, and restoration of the O<sub>2</sub> supply to tissues. TD CO<sub>2</sub> accelerates muscle injury repair by increasing O<sub>2</sub> delivery as well as mitochondrial biogenesis,

promoting VEGF upregulation to stimulate neovascularization and activating myogenesis to build muscle. TD CO<sub>2</sub> therapy also ameliorated the atrophy of skeletal muscle caused by nerve injury or following fracture [32,33].

## 2.5. Reduced Inflammation

In addition to its regenerative effects, CO<sub>2</sub> has anti-inflammatory effects. In laparoscopic rat models of sepsis, IP injection of CO<sub>2</sub>, but not helium or air, significantly increased survival in rats with lipopolysaccharide-induced sepsis [10]. This was accompanied by CO<sub>2</sub>-specific increases in plasma interleukin-10 (IL-10) levels and decreases in tumor necrosis factor-alpha (TNF-α) levels. The reduction in TNF-α levels correlated with the increase in survival and is consistent with previous demonstrations of IL-10-induced inhibition of macrophage-derived TNF-α production and suppression of nuclear factor kappa B (NF-κB) activation (responsible for the upregulation of many proinflammatory genes) as well as with studies showing that administration of recombinant IL-10 increases survival in septic animals and reduces inflammation [34,35,36,37].

The attenuation of the inflammatory response brought about by IP injection of CO<sub>2</sub>, including a reduction in the acute inflammatory response, was independent of peritoneal absorption of CO<sub>2</sub> and subsequent systemic acidosis (IP) [38]. Similar effects were noted in a pig study investigating the use of IP CO<sub>2</sub> gas vs. air during laparoscopic surgery [39]. Inflammatory responses were reduced by CO<sub>2</sub>, including a reduction in IL-6 release and peritoneal macrophage production of reactive O<sub>2</sub> species (ROS).

Another key anti-inflammatory response to elevated CO<sub>2</sub> was discovered in patients exhibiting hypercapnia (excessive CO<sub>2</sub> in the bloodstream) due to inadequate respiration caused by extensive

lung disease. These patients must be ventilated with minimal volumes to protect the lung from mechanical damage caused by lung stretching (ventilator-induced lung injury) so CO<sub>2</sub> levels remain elevated in the blood. Interestingly, controlling the rise in CO<sub>2</sub>, the so-called “permissive hypercapnia”, was found to improve lung inflammation and reduce morbidity and mortality in patients with acute respiratory distress syndrome (ARDS) (IH) [11]. While hypercapnia-induced acidosis boosts cardiac output, increases peripheral perfusion, and enhances tissue hemoglobin O<sub>2</sub> unloading, CO<sub>2</sub> can penetrate and act directly on cells to modulate intracellular pathways leading to inflammation and oxidative stress as well as pathways linked to cell survival, proliferation, and apoptosis [11]. This has relevance for patients with coronavirus disease 2019 (COVID-19), in which the viral spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds and disrupts the functioning of angiotensin-converting enzyme 2 (ACE2) on cell surfaces, leading to the activation of mitogen-activated protein kinases (MAPKs) and production of proinflammatory cytokines (e.g., interferon-gamma, IL-1 $\beta$ , IL-6, and TNF- $\alpha$ ) that cause pneumonia or ARDS [40]. The anti-inflammatory and antioxidant effects of increased tissue CO<sub>2</sub> could be beneficial for these patients.

## 2.6. Decreased Tumor Growth and Metastasis

Tumor hypoxia is a common feature of malignant tumors and contributes to their growth, invasiveness, and metastatic potential [41]. HIF-1 $\alpha$ , a key transcription factor induced by tissue hypoxia, regulates the transcription of genes involved in angiogenesis, cell survival, and tumor cell invasion. A hypoxic microenvironment also induces various molecular pathways that allow tumors to become resistant to chemotherapy, such as the induction of multidrug resistance (MDR) genes and radiation therapy. Multiple studies have

shown that TD CO<sub>2</sub> therapy can reduce tumor growth and metastasis [42,43,44,45,46], while one in vivo study showed that IA infusion of a carbonated solution reduced tumor growth in a liver tumor model [9]. Importantly, several of these studies demonstrated that CO<sub>2</sub> therapy enhances the effects of chemotherapy [9,45] and radiation therapy [44,46]. Thus, while CO<sub>2</sub> treatment alone can decrease the potential size of tumors, when CO<sub>2</sub> therapy is combined with chemotherapy or radiation, the response is even more effective. CO<sub>2</sub> therapy increases tumor cell apoptosis [9,42,43], which reduces tumor growth. The ability of CO<sub>2</sub> to increase blood flow could increase oxygenation of the tumor core, decreasing HIF-1α levels and reducing inflammation.

### 3. Mechanisms of Action of Carbon Dioxide Therapy

CO<sub>2</sub> has been seen simply as a by-product of cellular respiration, although it has roles in the control of breathing, acid–base balance, and cerebral blood flow [47]. The therapeutic effects of CO<sub>2</sub> noted above cannot be explained by our current dogma of CO<sub>2</sub> being carried in the blood away from tissues. Many new functions for tissue CO<sub>2</sub> have been revealed, emphasizing the importance of controlling CO<sub>2</sub> levels in tissues. The cellular and molecular mechanisms by which CO<sub>2</sub> therapy has its effects are only beginning to be elucidated.

#### 3.1. CO<sub>2</sub>/H<sup>+</sup> Concentrations and Carbonic Anhydrase Govern the Sensing of CO<sub>2</sub> in the Regulation of Cellular Function

This review describes the use of therapeutic CO<sub>2</sub>. It should be noted, however, that many of the findings described herein rely on the hydration of CO<sub>2</sub> and the production of protons to activate sensors

and initiate a response. While hydration happens spontaneously under physiological conditions, it happens as much as six orders of magnitude faster in the presence of the enzyme carbonic anhydrase (CA) [48]. CO<sub>2</sub> hydration via the action of CA is an important pathway for many responses. While the relative importance of protons and CA is discussed in the context of the effect of CO<sub>2</sub> on O<sub>2</sub> release from hemoglobin in red blood cells, there are many additional responses where hydration is noted. If not discussed, it does not mean that protons are not important. The role of protons is complicated by the fact that CO<sub>2</sub> can affect protons extracellularly, independent of how it affects protons intracellularly, indicating the importance of the location of the CA. As more is discovered about CO<sub>2</sub> biology, the relative significance of protons, and CA, in sensing the levels of CO<sub>2</sub> will come to light.

### 3.2. Increasing Blood Flow and Tissue Oxygenation

Increasing the tissue concentration of CO<sub>2</sub> increases blood flow to that tissue (CB, TD) [6,26], and increased blood flow stimulates flow-mediated dilation of blood vessels [49,50]. This vasodilator action is partly due to the CO<sub>2</sub>-induced production of NO by the endothelium (which acts via activation of cyclic GMP to relax the underlying smooth muscle) as it can be attenuated by inhibition of the enzyme endothelial NO synthase [21,51]. NO can also reduce arterial stiffness. Indeed, a single TD CO<sub>2</sub> treatment reduced arterial stiffness and, thus, peripheral vascular resistance in hypertensive patients [8]. However, this reduction in arterial stiffness by CO<sub>2</sub> is controlled by both endothelium-derived NO and endothelium-derived hyperpolarizing factor (EDHF) [52]. EDHF plays an important role in CO<sub>2</sub>-mediated shear stress-induced endothelium-dependent relaxation, and potassium channels, especially calcium-activated potassium (K<sub>Ca</sub>) channels, appear to be involved. EDHF-mediated hyperpolarization of the smooth muscle is evoked through

myo-endothelial junctions and/or the accumulation of  $K^+$  in the intercellular space.

$CO_2$ -induced vasodilation can also be endothelium-independent.  $CO_2$  reacts with water to form carbonic acid, which is in equilibrium with  $HCO_3^-$  and  $H^+$  ions. Elevating  $CO_2$  pushes the equilibrium toward more  $H^+$  ions. The resulting reduction in tissue pH inhibits contractility of the underlying smooth muscle in the blood vessel wall, leading to vasodilatation (CB) [50].  $CO_2$  in exercising skeletal muscle also activates perivascular sensory nerves, which release calcitonin gene-related peptide (CGRP) (IA) [53]. CGRP causes long-lasting local vasodilatation. Thus, during prolonged exhaustive exercise,  $CO_2$  liberated from exercising muscle can directly stimulate sensory nerves to release CGRP, while the local drop in pericellular pH may act together with  $CO_2$  to further activate sensory nerves, releasing more CGRP to dilate vessels and further increase blood flow [53]. This mechanism allows the vasodilatory response to occur locally, not systemically.

$CO_2$  and lactic acid are produced locally by metabolically active cells. The resultant decrease in intracellular pH provides a mechanism to balance vascular supply and metabolic activity by decreasing vascular resistance and increasing blood flow. While both  $CO_2$  and  $H^+$  individually can cause vasodilation via direct action on arterioles in skeletal muscle, they cannot conduct the spread of vasodilation throughout the microvascular network [54]. Instead, they likely work in concert to modify the effectiveness of other vasodilators. A physiological role for  $CO_2$  and pH in the regulation of coronary blood flow was initially proposed by Case and colleagues [55]. In an isolated heart preparation,  $CO_2$  evoked large increases in blood flow, presumably by generating adenosine (ADO) in the myocardium. The activation of ADO receptors on blood vessels by endogenously generated ADO contributes to the coronary

vasodilation that occurs in response to an increase in IA CO<sub>2</sub> and the resultant metabolic acidosis [56]. CO<sub>2</sub> has also been reported to cause the release of ADO from cultured vascular endothelial cells [57].

An alternative mechanism for CO<sub>2</sub>-mediated increases in blood flow involves connexins and the release of ATP, which can act on ATP-sensitive potassium (K<sub>ATP</sub>) channels in vascular smooth muscle to cause vasodilation, contributing both to resting blood flow and vasodilator-induced increases in flow. Connexins form large-pore channels that function either as dodecameric gap junctions or hexameric hemichannels to allow the regulated movement of small molecules and ions across cell membranes. Hemichannels are a particularly important mechanism for the release of ATP into the extracellular space [58]. CO<sub>2</sub> binds to a carbamylation motif in connexins Cx26, Cx30, and Cx32 and causes their hemichannels to open. Fluctuations in CO<sub>2</sub> levels within the tissue alter their open probability [59]. While it has been shown that direct CO<sub>2</sub>-gated Cx26 hemichannel opening and subsequent release of ATP mediate an important part of neurovascular coupling [47], the physiological significance of the CO<sub>2</sub> sensitivity of Cx30 and Cx32 has not yet been elucidated during exercise. Endothelial cells express Cx32, which participates in gap junctional communication [60], and endothelial cells have been shown to release ATP via connexin hemichannels [61]. It is possible that CO<sub>2</sub> binding to endothelial Cx32 could explain the release of ATP into the blood in skeletal muscle during exercise, as the source of ATP remains to be defined [62]. CO<sub>2</sub>-mediated CGRP release and the CA-dependent production of protons could also activate K<sub>ATP</sub> channels in vascular smooth muscle [63,64].


It should be noted that all the aforementioned mechanisms for CO<sub>2</sub>-dependent increases in blood flow are not relevant to pulmonary

circulation. Pulmonary circulation is unique. The role of CO<sub>2</sub> in controlling the distribution of pulmonary blood flow is small compared to the powerful effects of hypoxia and pulmonary vasoconstriction [65]. Data shows that CO<sub>2</sub> can induce both vasodilation and vasoconstriction, and it appears to depend on the level of resting vascular tone [66,67]. In sharp contrast to the peripheral vasculature, where protons cause vasodilation, CO<sub>2</sub> and the CA-dependent production of carbonic acid cause vasoconstriction in the pulmonary vascular network [68].

In the in vivo hamster cheek pouch, CO<sub>2</sub> alters both microvessel diameter and the perivascular partial pressure of O<sub>2</sub> (pO<sub>2</sub>), as demonstrated by using microelectrodes to measure O<sub>2</sub> [69]. When the CO<sub>2</sub> concentration of the superfusion solution was increased, the tissue O<sub>2</sub> concentration also increased [69]. Since increased O<sub>2</sub> tensions cause vasoconstriction, there may be a limit to how much blood flow can increase as the CO<sub>2</sub> rises. This may explain the limited increases seen in cremaster blood flow when CO<sub>2</sub> in the superfusion solution was elevated above 10% [54].

Finally, it has been shown in the human forearm that there is enhanced O<sub>2</sub> release from hemoglobin when CO<sub>2</sub> is applied to the skin (TD) [70]. This CO<sub>2</sub>-based elevation in tissue oxygenation can be explained by the Bohr effect, a rightward shift of the O<sub>2</sub>-hemoglobin dissociation curve with an increase in pCO<sub>2</sub> or a decrease in pH [71]. This relationship was discovered in 1904 by Christian Bohr [71], who showed that increased CO<sub>2</sub> tensions decreased the O<sub>2</sub> affinity of whole blood in dogs. It should be noted, however, that Malte et al. showed that the protons generated by CA have a larger effect on the binding of O<sub>2</sub> to hemoglobin than does CO<sub>2</sub> itself (Figure 1) [72].

Figure 1.



[Open in a new tab](#)

The Bohr effect, as defined by  $\text{CO}_2$  and protons. The Bohr and Haldane effects have been modeled to describe the interactions between  $\text{O}_2$  and  $\text{CO}_2$  binding to hemoglobin [72]. The Bohr effect describes how  $\text{O}_2$  binding is decreased in the presence of  $\text{CO}_2$  and protons. Graph (A) shows the traditional oxygen (A) equilibrium curves modeled under different levels of  $\text{CO}_2$ . The three black curves are the oxygen equilibrium curves obtained when the partial pressure of  $\text{CO}_2$  is held constant at the indicated values. The blue curve is obtained when  $\text{CO}_2$  is added at the same time as oxygen is removed at a gas exchange ratio, respiratory quotient (RQ), of 0.83. Graph (B) shows the effect of protons (B) on binding with a constant  $\text{PCO}_2$  value of 40 mmHg and pH 7.2 at a  $\text{PO}_2$  of 100 mmHg. Protons bind to the Bohr groups on the hemoglobin. The five oxygen equilibrium curves are obtained by increasing the number of bound Bohr groups (i.e., protons bound), as indicated by the numbers on the curves. The pH is not displayed because it is a poor indicator of proton binding. As protons are bound to hemoglobin, the pH increases. Figures are reprinted/adapted with permission from Ref. [72].

Copyright year 2018, Journal of Applied Physiology.

There are two Bohr groups on each hemoglobin moiety, allowing a total of eight protons to interact with the hemoglobin molecule. In the red blood cell,  $\text{CO}_2$  is rapidly interconverted to  $\text{HCO}_3^-$  and  $\text{H}^+$  ions via CA to generate the protons that can cause this effect. In the absence of  $\text{CO}_2$  and protons, hemoglobin will bind  $\text{O}_2$  until it reaches tissue that is essentially anoxic. Thus, tissues with low metabolism or which may be exposed to the body surface will have low  $\text{CO}_2$  levels and, therefore, will receive little  $\text{O}_2$  from the blood that may be flowing through the tissue. Elevating  $\text{CO}_2$  to generate protons will force the rightward shift in curves so that  $\text{O}_2$  will be released from hemoglobin and delivered to the tissue [Graph A]. The rightward shift caused by  $\text{CO}_2$  alone is relatively limited.

When external  $\text{CO}_2$  is applied, the  $\text{CO}_2$  is hydrated in the presence of CA, and higher concentrations of protons are produced. The rapid hydration of  $\text{CO}_2$  maintains the driving force for the diffusion of  $\text{CO}_2$  into the red blood cell and prevents the loss of  $\text{CO}_2$  by conversion to  $\text{HCO}_3^-$ . The effect of protons on oxygen binding is dramatic and decreases the binding of the oxygen, as defined in Graph B. When hemoglobin binds protons during the release of oxygen, it acts as a buffer. pH will actually increase, so red cell pH is not a good indicator of proton binding to hemoglobin. According to Malte and Lykkeboe, "The Bohr effect is exerted by protons preloaded on the Bohr groups at the given pH, as well as the protons taken up by the Bohr groups during gas exchange. The proton preload sets the oxygen affinity (i.e., the  $P_{50}$ ) at the beginning of the gas exchange. The protons taken up during gas exchange lead to a further progressive decrease in oxygen affinity. The concerted effect of these two processes is very large, and the size of the Bohr effect has a direct influence on the oxygen affinity

of hemoglobin.” [72].

Hartmann et al. [23] proposed that an increase in tissue O<sub>2</sub> pressure caused by bathing with CO<sub>2</sub>-enriched water was due to the Bohr effect, but they were unable to show this directly. Sakai et al. [70] utilized near-infrared spectroscopy to track dynamic changes in tissue oxy- and deoxyhemoglobin levels in real-time, directly demonstrating that TD CO<sub>2</sub> application causes O<sub>2</sub> dissociation from oxy-hemoglobin, i.e., the Bohr effect, in humans.

### 3.3. Enhancing Angiogenesis

While a single treatment with CO<sub>2</sub> can stimulate vasodilation and enhance O<sub>2</sub> release from hemoglobin due to the Bohr effect, repeated CO<sub>2</sub> applications maintain the tissue O<sub>2</sub> supply and induce angiogenesis [6,15,18,26,28,32,33,73]. Responses to CO<sub>2</sub> include increases in basic fibroblast growth factor [2,8], VEGF [6,15,18,26,28,32,33,73], SIRT1 [28], PGC-1α [16,17,20,22], and NO [26,73], all linked to neovascularization. Angiogenesis is a critical part of the healing process and is known to occur in response to tissue hypoxia. Hypoxia induces the transcription of angiogenic genes, such as VEGF, in part by the stabilization of hypoxia-inducible transcription factors [74]. A deficiency in blood flow leads to hypoxia, and elevated levels of CO<sub>2</sub> accumulate in the tissue.

Interestingly, while the therapeutic introduction of CO<sub>2</sub> causes angiogenesis, it decreases or prevents the production of HIF-1α [9,12,15,42,43,44,45,46,75,76]. One mechanism for CO<sub>2</sub>-mediated suppression of HIF-1α is via a pH-dependent, O<sub>2</sub>-independent degradation of HIF-1α [75]. Selfridge et al. proposed that elevated CO<sub>2</sub> promotes lysosomal degradation of HIF-α subunits in an environment of decreasing intracellular pH rather than induction of proteasomal degradation [75]. Galganska et al. showed that a single

treatment with CO<sub>2</sub> efficiently inhibited HIF-1 $\alpha$  expression in cultured human endothelial cells [40]. Alternatively, the decrease in HIF-1 $\alpha$  could simply be the result of the increased oxygenation generated by the increased blood flow and increased release of oxygen because of the Bohr effect, as described above. Thus, while CO<sub>2</sub> is a potent trigger for angiogenesis linked to hypoxia, it appears to raise VEGF levels via a non-HIF1 pathway.

Similarly, a non-HIF-mediated process may occur in skeletal muscle in response to exercise. Exercise generates high concentrations of CO<sub>2</sub> in the skeletal muscle, and CO<sub>2</sub> stimulates PGC-1 $\alpha$  [77,78]. PGC-1 $\alpha$  is a metabolic sensor induced by hypoxia that regulates VEGF expression and angiogenesis in cultured muscle cells and skeletal muscle in vivo [79]. PGC-1 $\alpha$  promotes angiogenesis through interaction with estrogen-related receptor-alpha (ERR $\alpha$ ), an orphan nuclear receptor that binds to the promoter region and a novel enhancer in the first intron of the VEGF gene to initiate robust VEGF gene activation in a HIF-independent manner [79,80,81]. A reduced increase in VEGF expression in PGC-1 $\alpha$  knockout mice following exercise demonstrates the functional relevance of this non-HIF-1 $\alpha$  pathway in coordinating the angiogenic response to exercise [80].

In contrast, Sopariwala et al. demonstrated that ERR $\alpha$  is a hypoxia-stimulated factor that activates a paracrine angiogenic gene program to promote normal as well as ischemic angiogenesis in skeletal muscle in a HIF-1-dependent manner [82]. In endothelial cells, ERR $\alpha$  receptors were positively linked to angiogenesis, as downregulation of ERR $\alpha$  receptors decreased angiogenesis [83]. This reduction in angiogenesis was mediated by inhibition of HIF-1 $\alpha$  expression as well as inhibition of the phosphatidylinositol-3-kinase/protein kinase B (Akt)/signal transducer and activator of transcription (PI3K/Akt/STAT3) pathway. Likhite et al., however, reported that ERR $\alpha$  receptors act as negative regulators of

angiogenesis by transcriptionally repressing angiogenic genes [84]. The link between angiogenesis and exercise/ischemia is indeed complex, and further experimentation will be needed to elucidate the role of ERRA receptors.

The CO<sub>2</sub> sensor triggering the angiogenic process has yet to be defined. Connexins have recently been shown to bind CO<sub>2</sub> [58]. Cx32 is expressed on endothelial cells and regulates angiogenesis by enhancing tube formation and cell migration [85]. It is conceivable that CO<sub>2</sub> binding to Cx32 initiates neovascularization in response to chronic tissue hypoxia. An alternate candidate for a tissue CO<sub>2</sub> sensor is ubiquitin. While much of the control of angiogenic events is instigated through hypoxia-induced VEGF expression, the ubiquitin–proteasome system plays a central role in fine-tuning the functions of core proangiogenic proteins, including VEGF, VEGF receptors, angiogenic signaling proteins, and other non-VEGF pathways [86]. Ubiquitin is a highly conserved protein that regulates both protein activity and protein degradation through conjugation to target proteins [86,87]. CO<sub>2</sub> binds to lysine residues in ubiquitin, forming carbamate, and this reversible carbamylation reaction may be involved in the diverse physiological responses to fluctuating pCO<sub>2</sub> levels. Linthwaite et al. described multiple locations where CO<sub>2</sub> could bind to ubiquitin and alter its properties [87]. Deng et al. described how the deubiquitination of AMPK is critical for its activation [88]. AMPK is a crucial sensor of cellular energy, and it is activated when intracellular ATP concentrations decrease, and AMP or ADP concentrations increase in response to energy or pathological stresses [89]. AMPK activation plays a critical role in the activation of PGC-1 $\alpha$  and, thereby, could be the link between CO<sub>2</sub> and exercise to initiate non-HIF-mediated angiogenesis [81].

### 3.4. Stimulating Skeletal Muscle Mitochondrial

## Biogenesis

Mitochondria are critical for aerobic ATP synthesis and proper cell function. Mitochondrial quantity and quality in skeletal muscle are not only important for performance but also relevant to health, as mitochondrial dysfunction is associated with muscle atrophy, diabetes, and aging. Mitochondrial biogenesis, an increase in mitochondrial number and function, is instrumental in exercise training-induced improvement of muscle function but is also important for conferring cytoprotection against several damaging stimuli and for maintaining whole-body metabolic homeostasis. As noted above, for angiogenesis, the molecular mechanisms triggered by therapeutic CO<sub>2</sub> appear to mimic the mechanisms induced by exercise. Consistent with the known effects of PGC-1 $\alpha$ , TD CO<sub>2</sub>, similar to exercise, increases mitochondrial biogenesis [28,30]. Oxidative and metabolic stresses induced by contractile activity in skeletal muscle stimulate PGC-1 $\alpha$  expression and activity, which in turn promotes mitochondrial biogenesis through interactions with nuclear transcription factors nuclear respiratory factor 1 (NRF1) and NRF2 [81]. The coactivation of NRF1 and NRF2 by PGC-1 $\alpha$  also induces mitochondrial transcription factor A (TFAM), which regulates mitochondrial DNA transcription [81]. PGC-1 $\alpha$  thus coordinates the expression of both nuclear- and mitochondrial-encoded genes. As noted above, the exact mechanism(s) by which CO<sub>2</sub>, exercise, and contractile activity bring about activation of PGC-1 $\alpha$  are not known, although p38 $\gamma$ 3 MAPK, an upstream stress-activated kinase for PGC-1 $\alpha$ , may have a role in activating mitochondrial biogenesis [81]. AMPK phosphorylates PCG-1a on several sites, leading to increased activation, while SIRT1 activates PCG-1a directly by removing acetylation groups on 13 lysines [90].

### 3.5. Reducing Inflammation

Some of the beneficial effects of therapeutic CO<sub>2</sub> may be related to its ability to suppress inflammatory signaling and elevated ROS. Hypoxia, HIF-1 $\alpha$ , and increased expression of glycolytic enzymes are linked to inflammation, and NF- $\kappa$ B can drive increased HIF-1 $\alpha$  expression. Loss of oxygen supply, depletion of energy, and increased oxidative stress in ischemia/hypoxia result in the reduction of ATP synthesis and initiate a cascade of pathways that lead to cell death if not reversed. SIRT1 plays a major role in protecting against cellular stress and in controlling metabolic pathways during ischemia/hypoxia.

CO<sub>2</sub> can elicit a specific repertoire of transcriptional events in a dose-dependent fashion [91]. NF- $\kappa$ B is the master regulator of the sensing and signaling pathways that induce the transcription of multiple proinflammatory genes. As described in the studies noted above and others [10,91], CO<sub>2</sub> can counteract inflammation to restore homeostasis. CO<sub>2</sub> disrupts inflammation by binding to ubiquitin. Once CO<sub>2</sub> is bound, ubiquitin will remodel and transform into a proteasome that will directly diminish the NF- $\kappa$ B response [87,92]. During deubiquitination, ubiquitin is removed from a substrate to release its activity. This has been described as CO<sub>2</sub>-induced de-activation of NF- $\kappa$ B [92].

Alternatively, studies in human cells demonstrated that CO<sub>2</sub> directly inhibited the activation of the MAPKs extracellular signal-regulated kinases 1 and 2 (ERK1/2) by the receptor-binding domain of the SARS-CoV-2 spike protein, independent of pH and independent of upstream activators, blocking the rise in proinflammatory cytokine production. Thus, ERK1/2 act as a direct CO<sub>2</sub> sensor, mediating the anti-inflammatory response of elevated CO<sub>2</sub> [40].

### 3.6. Antioxidant Effects

The presence of CO<sub>2</sub> is essential for life due to its antioxidant effects. While CB CO<sub>2</sub> can decrease inflammation, it will also reduce the ROS generated during the various phases of inflammation [93,94,95]. As Veselá and Wilhelm noted [95], CO<sub>2</sub> prevents nitration and oxidative damage by scavenging peroxynitrite. Moreover, CO<sub>2</sub> can protect superoxide dismutase from hydrogen-peroxide-induced damage, although this does result in the formation of carbonate radicals that can propagate oxidative damage. The most significant antioxidant role for CO<sub>2</sub> in vivo is its ability to stabilize the iron–transferrin complex and thereby prevent the involvement of this complex in the initiation of free radical reactions [95].

While the evidence of the relationship between CO<sub>2</sub> therapy and oxidative stress is limited, Veselá and Wilhelm found that CO<sub>2</sub> plays a protective role in scavenging free radicals and suppressing oxidative metabolism [95]. A recent study demonstrated that CO<sub>2</sub> treatment could reduce the level of asymmetric dimethylarginine, which is a marker of oxidative stress [96].

### 3.7. Benefits of Diabetes Mellitus

Microvascular disease caused by diabetes is a potential target for CO<sub>2</sub> therapy. Studies have shown that the basic status of the microvasculature is one of low O<sub>2</sub> and low metabolism, although the role of HIF-1 $\alpha$  in the tissue response to hyperglycemia and hypoxia appears to be rather variable [97]. HIF-1 $\alpha$  plays an unpredictable role in the response of the tissue to hyperglycemia, and current data suggest that it is probably better to activate the CO<sub>2</sub> hypoxemic response than the HIF-1 $\alpha$  hypoxic pathway. Hyperglycemia triggers the glycolytic pathway for ATP production. This pathway generates less CO<sub>2</sub> compared to aerobic respiration. Therefore, the concentrations of CO<sub>2</sub> in the tissue are lower than normal. This sets

up an environment with low oxygenation, increased inflammation, and reduced capillary density. Notably, exercise can reduce these complications of diabetes [98], and it appears that CO<sub>2</sub> therapy can mimic these same effects [28] as well as re-balance the pro- and anti-factors controlling angiogenesis, such as VEGF, endothelial NO synthase, and thrombospondin-1 [26].

### 3.8. Reducing Tumor Hypoxia

Tumor growth is limited by the need for O<sub>2</sub> and the limited diffusion of nutrients. Solid tumors display a hypoxic core that stimulates pathways triggered by HIF-1α [43,45,99]. As noted above, numerous studies have consistently confirmed that CO<sub>2</sub> therapy will decrease the size of tumors by reducing the hypoxic core of the tumor, reversing the stabilization of HIF-1α to modulate survival pathways, and triggering non-HIF-related pathways [43,45,99]. CO<sub>2</sub> therapy results in an oxygenated core in the tumor that increases tumor cell apoptosis and enhances sensitivity to chemotherapy and radiation therapy. A collection of studies describes multiple mechanisms that could come together, leading to apoptosis due to the presence of CO<sub>2</sub> and improved oxygenation. These pathways involve increases in intracellular calcium, AMPK, PGC-1α, and caspases 3 and 9 [28,76,100,101,102,103,104,105].


## 4. Summary

---

Therapeutic CO<sub>2</sub> gas has been found to be effective for many microvascular disorders. [Figure 2](#) summarizes some of the tissue responses to hypoxia and elevated CO<sub>2</sub> and demonstrates how CO<sub>2</sub> protects the tissue from progressing toward survival mode (e.g., by reducing HIF-1α and activating AMPK) when hypoxia is severe and/or sustained. Elevated CO<sub>2</sub> activates mechanisms that pull the microenvironment toward a “thrive mode” that maintains

homeostasis. Physiological properties triggered by CO<sub>2</sub> include elevated oxygenation, increased angiogenesis, increased mitochondrial biogenesis, anti-inflammation, reduced oxidative stress, and increased tissue blood flow. The balance between pro-inflammatory and anti-inflammatory phases is also pushed toward homeostasis when tissue CO<sub>2</sub> is elevated. This is critical for healing wounds and fractures. Hyperglycemia in diabetes leads to poor oxygenation, loss of capillaries, and inflammation. Diabetes is a risk factor for peripheral arterial disease and reduced blood flow, often leading to chronic wounds. Therapeutic CO<sub>2</sub> corrects this and restores homeostasis. Tumors have a hypoxic core that keeps metastatic cells alive due to pathways that are triggered by HIF-1 $\alpha$ . Therapeutic CO<sub>2</sub> can help oxygenate the hypoxic core and reduce HIF-1 $\alpha$ . Finally, evidence supports the thesis that CO<sub>2</sub> is a critical metabolic factor during exercise that triggers angiogenesis, mitochondrial biogenesis, and myocyte fiber switching. Thus, CO<sub>2</sub> is not only a metabolic waste product but may be a gaseous signaling molecule, similar to NO, carbon monoxide, and hydrogen sulfide. Modulating its levels via therapeutic application may provide a path to multiple important health solutions.

Figure 2.



[Open in a new tab](#)

Tissue response to hypoxia and carbon dioxide. This chart shows the molecular pathways that are involved in the tissue response to hypoxia and elevated CO<sub>2</sub> levels. Three pathways are shown. The first two are tissue responses to hypoxia. Normal metabolic control of hypoxia initially involves the moment-to-moment response to O<sub>2</sub> demands by alterations in blood flow. If demand persists, pathways for improving O<sub>2</sub> supply are activated. Multiple pathways lead to the activation of PGC-1α, which induces metabolic changes and new blood vessel formation to allow the tissue to continue to thrive. If hypoxia is persistent and/or severe, as seen in pathological conditions, the left pathway is also activated. Cells experience increased inflammation and oxidative stress and activate HIF-1α-induced production of VEGF to further stimulate neovascularization and increase blood flow while also altering cell metabolism to reduce cell death (i.e., stimulate survival mode). The right pathway shows the responses activated by increases in tissue CO<sub>2</sub>. When blood flow is limited, CO<sub>2</sub> levels rise and trigger activation of AMPK, stimulating the tissue to respond with changes in cell metabolism and neovascularization that allow the tissue to thrive. Multiple additional pathways are stimulated by elevated CO<sub>2</sub>, resulting in increased blood flow, decreased inflammation, decreased oxidative stress, as well as a reduction in survival pathways stimulated by HIF-1α. Thus, elevated CO<sub>2</sub> levels (either metabolically generated or brought about by therapeutic CO<sub>2</sub> delivery) will produce a more homeostatic state in the tissue.

## Abbreviations

---

ACE2	angiotensin-converting enzyme 2
ADO	adenosine
AMP	adenosine monophosphate
AMPK	AMP-activated protein kinase
ARDS	acute respiratory distress syndrome
ATP	adenosine triphosphate
CA	carbonic anhydrase
CB	carbonated water bath
CG	carbonated paste or gel
cGMP	cyclic guanosine monophosphate
CGRP	calcitonin gene-related peptide
CO <sub>2</sub>	carbon dioxide
COX	cytochrome c oxidase
COVID-19	coronavirus disease 2019
CS	citrate synthase
EDHF	endothelium-derived hyperpolarizing factor
eNOS	endothelial nitric oxide synthase
ERK1/2	extracellular signal-regulated kinase 1/2
ERR $\alpha$	orphan nuclear receptor estrogen-related receptor-alpha
H <sup>+</sup>	hydrogen proton
HIF-1 $\alpha$	hypoxia-inducible factor 1-alpha
IA	intra-arterial infusion of a carbonated solution
IH	inhaled CO <sub>2</sub> or hypercarbia due to

	hypoventilation
IL-10	interleukin-10
IL-1 $\beta$	interleukin 1 beta
IL-6	interleukin 6
IP	intraperitoneal insufflation of CO <sub>2</sub>
ITC	iron–transferrin complex
K <sub>Ca</sub>	calcium-activated potassium
K <sub>ATP</sub>	ATP-sensitive potassium
MAPKs	mitogen-activated protein kinases
MDM-2	mouse double minute 2
NAD <sup>+</sup>	nicotinamide adenine dinucleotide
NF- $\kappa$ B	nuclear factor- $\kappa$ B
NO	nitric oxide
NRF1, NRF2	nuclear transcription factors nuclear respiratory factor 1, 2
O <sup>-2</sup>	superoxide
O <sub>2</sub>	molecular oxygen
p38 MAP- kinase	mitogen-activated protein (MAP) kinase
PGC-1 $\alpha$	peroxisome proliferator-activated receptor- gamma coactivator—1 alpha
ROS	reactive oxygen species
SARS- CoV-2	severe acute respiratory syndrome coronavirus 2
SIRT1	sirtuin 1
SQ	subcutaneous injections of CO <sub>2</sub>

STZ	streptozotocin
TD	transdermal application of CO <sub>2</sub>
TFAM	mitochondrial transcription factor A
TNF- $\alpha$	tumor necrosis factor-alpha
TSP-1t	hrombospondin 1
VEGF	vascular endothelial growth factor

[Open in a new tab](#)

## Author Contributions

---

Both authors contributed to the conceptualization, analysis, writing, reviewing, and editing of this manuscript. All authors have read and agreed to the published version of the manuscript.

## Institutional Review Board Statement

---

Not applicable.

## Informed Consent Statement

---

Not applicable.

## Data Availability Statement

---

All data reported is publicly available.

## Conflicts of Interest

---

R.J. Rivers is a scientific advisor to Serendi Medical, LL. C.J.

Meininger has no conflicts of interest.

## Funding Statement

---

This research received no external funding.

## Footnotes

---

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

## References

---

1. Crystal G.J. Carbon dioxide and the heart: Physiology and clinical implications. *Anesth. Analg.* 2015;121:610–623. doi: 10.1213/ANE.0000000000000820. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
2. Reglin B., Pries A.R. Metabolic control of microvascular networks: Oxygen sensing and beyond. *J. Vasc. Res.* 2014;51:376–392. doi: 10.1159/000369460. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
3. Kierans S.J., Taylor C.T. Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular

- physiology. *J. Physiol.* 2021;599:23–37. doi: 10.1113/JP280572. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
4. Rodríguez C., Muñoz M., Contreras C., Prieto D. AMPK, metabolism, and vascular function. *FEBS J.* 2021;288:3746–3771. doi: 10.1111/febs.15863. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
5. Bottoni P, Óvári M., Záray G., Caroli S. Characteristics of spring waters in budapest: A short review. *Microchem. J.* 2013;110:770–774. doi: 10.1016/j.microc.2013.09.002. [[DOI](#)] [[Google Scholar](#)]
6. Xu Y.-J., Elimban V., Bhullar S.K., Dhalla N.S. Effects of CO2 water-bath treatment on blood flow and angiogenesis in ischemic hind limb of diabetic rat. *Can. J. Physiol. Pharmacol.* 2018;96:1017–1021. doi: 10.1139/cjpp-2018-0160. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
7. Yatagai N., Hasegawa T., Amano R., Saito I., Arimoto S., Takeda D., Kakei Y., Akashi M. Transcutaneous carbon dioxide decreases immunosuppressive factors in squamous cell carcinoma. *In Vivo. BioMed Res. Int.* 2021;2021:1–9. doi: 10.1155/2021/5568428. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
8. Németh B., Kiss I., Ajtay B., Péter I., Kreska Z., Cziráki A., Horváth I.G., Ajtay Z. Transcutaneous carbon dioxide treatment is capable of reducing peripheral vascular resistance in hypertensive patients. *Vivo.* 2018;32:1555–1559. doi: 10.21873/invivo.11414. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
9. Katayama N., Sugimoto K., Okada T., Ueha T., Sakai Y., Akiyoshi H., Mie K., Ueshima E., Sofue K., Koide Y., et al.

Intra-arterially infused carbon dioxide-saturated solution for sensitizing the anticancer effect of cisplatin in a rabbit VX2 liver tumor model. *Int. J. Oncol.* 2017;51:695–701. doi: 10.3892/ijo.2017.4056. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

10. Hanly E.J., Fuentes J.M., Aurora A.R., Bachman S.L., De Maio A., Marohn M.R., Talamini M.A. Carbon dioxide pneumoperitoneum prevents mortality from sepsis. *Surg. Endosc.* 2006;20:1482–1487. doi: 10.1007/s00464-005-0246-y. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

11. Contreras M., Masterson C., Laffey J.G. Permissive hypercapnia: What to remember. *Curr. Opin. Anaesthesiol.* 2015;28:26–37. doi: 10.1097/ACO.000000000000151. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

12. Amano-Iga R., Hasegawa T., Takeda D., Murakami A., Yatagai N., Saito I., Arimoto S., Kakei Y., Sakakibara A., Akashi M. Local application of transcutaneous carbon dioxide paste decreases inflammation and accelerates wound healing. *Cureus.* 2021;13:e19518. doi: 10.7759/cureus.19518. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

13. Ahramiyanpour N., Shafie’ei M., Sarvipour N., Amiri R., Akbari Z. Carboxytherapy in dermatology: A systematic review. *J. Cosmet. Dermatol.* 2022;21:1874–1894. doi: 10.1111/jocd.14834. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

14. Oda T., Iwakura T., Fukui T., Oe K., Mifune Y., Hayashi S., Matsumoto T., Matsushita T., Kawamoto T., Sakai Y., et al. Effects of the duration of transcutaneous CO<sub>2</sub> application on the facilitatory effect in rat fracture repair. *J. Orthop. Sci.* 2020;25:886–891. doi: 10.1016/j.jos.2019.09.017. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

15. Saito I., Hasegawa T., Ueha T., Takeda D., Iwata E., Arimoto S., Sakakibara A., Sakakibara S., Akashi M., Sakai Y., et al. Effect of local application of transcutaneous carbon dioxide on survival of random-pattern skin flaps. *J. Plast. Reconstr. Aesthet. Surg.* 2018;71:1644–1651. doi: 10.1016/j.bjps.2018.06.010. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
16. Wollina U., Heinig B., Uhlemann C. Transdermal CO<sub>2</sub> application in chronic wounds. *Int. J. Low. Extrem Wounds.* 2004;3:103–106. doi: 10.1177/1534734604265142. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
17. Macura M., Ban Frangez H., Cankar K., Finžgar M., Frangez I. The effect of transcutaneous application of gaseous CO<sub>2</sub> on diabetic chronic wound healing—A double-blind randomized clinical trial. *Int. Wound J.* 2020;17:1607–1614. doi: 10.1111/iwj.13436. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
18. Koga T., Niikura T., Lee S.Y., Okumachi E., Ueha T., Iwakura T., Sakai Y., Miwa M., Kuroda R., Kurosaka M. Topical cutaneous CO<sub>2</sub> application by means of a novel hydrogel accelerates fracture repair in rats. *J. Bone Jt. Surg.* 2014;96:2077–2084. doi: 10.2106/JBJS.M.01498. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
19. Niikura T., Iwakura T., Omori T., Lee S.Y., Sakai Y., Akisue T., Oe K., Fukui T., Matsushita T., Matsumoto T., et al. Topical cutaneous application of carbon dioxide via a hydrogel for improved fracture repair: Results of phase I clinical safety trial. *BMC Musculoskelet. Disord.* 2019;20:563. doi: 10.1186/s12891-019-2911-7. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

20. Izumi Y, Yamaguchi T, Yamazaki T, Yamashita N, Nakamura Y, Shiota M, Tanaka M, Sano S, Osada-Oka M, Shimada K, et al. Percutaneous carbon dioxide treatment using a gas mist generator enhances the collateral blood flow in the ischemic hindlimb. *J. Atheroscl. Thromb.* 2015;22:38–51. doi: 10.5551/jat.23770. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
21. Irie H, Tatsumi T, Takamiya M, Zen K, Takahashi T, Azuma A, Tateishi K, Nomura T, Hayashi H, Nakajima N, et al. Carbon dioxide-rich water bathing enhances collateral blood flow in ischemic hindlimb via mobilization of endothelial progenitor cells and activation of NO-cGMP system. *Circulation.* 2005;111:1523–1529. doi: 10.1161/01.CIR.0000159329.40098.66. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
22. Toriyama T, Kumada Y, Matsubara T, Murata A, Ogino A, Hayashi H, Nakashima H, Takahashi H, Matsuo H, Kawahara H. Effect of artificial carbon dioxide foot bathing on critical limb ischemia (fontaine IV) in peripheral arterial disease patients. *Int. Angiol.* 2002;21:367–373. [[PubMed](#)] [[Google Scholar](#)]
23. Hartmann B.R., Bassenge E., Hartmann M. Effects of serial percutaneous application of carbon dioxide in intermittent claudication: Results of a controlled trial. *Angiology.* 1997;48:957–963. doi: 10.1177/000331979704801104. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
24. Fabry, Monnet, Schmidt, Lusson, Carpentier, Baguet, Dubray Clinical and microcirculatory effects of transcutaneous CO<sub>2</sub> therapy in intermittent claudication. randomized double-blind clinical trial with a parallel design. *Vasa.* 2009;38:213–224. doi: 10.1024/0301-1526.38.3.213. [[DOI](#)] [[PubMed](#)]

[\[Google Scholar\]](#) ]

25. Kivelä R., Silvennoinen M., Touvra A., Lehti T.M., Kainulainen H., Vihko V. Effects of experimental type 1 diabetes and exercise training on angiogenic gene expression and capillarization in skeletal muscle. *FASEB J.* 2006;20:1570–1572. doi: 10.1096/fj.05-4780fje. [\[DOI\]](#) ]

[\[PubMed\]](#) [\[Google Scholar\]](#) ]

26. Matsumoto T., Tanaka M., Ikeji T., Maeshige N., Sakai Y., Akisue T., Kondo H., Ishihara A., Fujino H. Application of transcutaneous carbon dioxide improves capillary regression of skeletal muscle in hyperglycemia. *J. Physiol. Sci.* 2019;69:317–326. doi: 10.1007/s12576-018-0648-y. [\[DOI\]](#) ]

[\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#) ]

27. Matsumoto T., Tanaka M., Nakanish R., Takuwa M., Hirabayashi T., Ono K., Ikeji T., Maeshige N., Sakai Y., Akisue T., et al. Transcutaneous carbon dioxide attenuates impaired oxidative capacity in skeletal muscle in hyperglycemia model. *Gen. Physiol. Biophys.* 2019;38:237–244. doi:

10.4149/gpb\_2018048. [\[DOI\]](#) ] [\[PubMed\]](#) [\[Google Scholar\]](#) ]

28. Oe K., Ueha T., Sakai Y., Nikura T., Lee S.Y., Koh A., Hasegawa T., Tanaka M., Miwa M., Kurosaka M. The effect of transcutaneous application of carbon dioxide (CO<sub>2</sub>) on skeletal muscle. *Biochem. Biophys. Res. Commun.* 2011;407:148–152. doi: 10.1016/j.bbrc.2011.02.128. [\[DOI\]](#) ]

[\[PubMed\]](#) [\[Google Scholar\]](#) ]

29. Akamine T., Taguchi N. Effects of an artificially carbonated bath on athletic warm-up. *J. Hum. Ergol.* 1998;27:22–29. doi: 10.11183/jhe1972.27.22. [\[DOI\]](#) ] [\[PubMed\]](#) [\[Google](#)

[Scholar\]](#) ]

30. Ueha T., Oe K., Miwa M., Hasegawa T., Koh A., Nishimoto H., Lee S., Niikura T., Kurosaka M., Kuroda R., et al. Increase in carbon dioxide accelerates the performance of endurance exercise in rats. *J. Physiol. Sci.* 2018;68:463–470. doi: 10.1007/s12576-017-0548-6. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
31. Akahane S., Sakai Y., Ueha T., Nishimoto H., Inoue M., Niikura T., Kuroda R. Transcutaneous carbon dioxide application accelerates muscle injury repair in rat models. *Int. Orthop.* 2017;41:1007–1015. doi: 10.1007/s00264-017-3417-2. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
32. Nishimoto H., Inui A., Ueha T., Inoue M., Akahane S., Harada R., Mifune Y., Kokubu T., Nishida K., Kuroda R., et al. Transcutaneous carbon dioxide application with hydrogel prevents muscle atrophy in a rat sciatic nerve crush model. *J. Orthop. Res.* 2018;36:1653–1658. doi: 10.1002/jor.23817. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
33. Inoue M., Sakai Y., Oe K., Ueha T., Koga T., Nishimoto H., Akahane S., Harada R., Lee S.Y., Niikura T., et al. Transcutaneous carbon dioxide application inhibits muscle atrophy after fracture in rats. *J. Orthop. Sci.* 2020;25:338–343. doi: 10.1016/j.jos.2019.03.024. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
34. Howard M., Muchamuel T., Andrade S., Menon S. Interleukin 10 protects mice from lethal endotoxemia. *J. Exp. Med.* 1993;177:1205–1208. doi: 10.1084/jem.177.4.1205. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
35. Rongione A.J., Kusske A.M., Ashley S.W., Reber H.A., McFadden D.W. Interleukin-10 prevents early cytokine release in severe intraabdominal infection and sepsis. *J. Surg. Res.*

1997;70:107–112. doi: 10.1006/jsre.1997.5071. [[DOI](#) ]

[[PubMed](#)] [[Google Scholar](#) ]

36. Rongione A.J., Kusske A.M., Kwan K., Ashley S.W., Reber H.A., McFadden D.W. Interleukin-10 protects against lethality of intra-abdominal infection and sepsis. *J. Gastrointest. Surg.* 2000;4:70–76. doi: 10.1016/S1091-255X(00)80035-9.

[[DOI](#) ] [[PubMed](#)] [[Google Scholar](#) ]

37. Yoshidome H., Kato A., Edwards M.J., Lentsch A.B. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: Implications of a central role for nuclear factor  $\kappa$ B. *Hepatology.* 1999;30:203–208. doi: 10.1002/hep.510300120.

[[DOI](#) ] [[PubMed](#)] [[Google Scholar](#) ]

38. Hanly E.J., Bachman S.L., Marohn M.R., Boden J.H., Herring A.E., De Maio A., Talamini M.A. Carbon dioxide pneumoperitoneum–mediated attenuation of the inflammatory response is independent of systemic acidosis. *Surgery.* 2005;137:559–566. doi: 10.1016/j.surg.2005.01.005.

[[DOI](#) ] [[PubMed](#)] [[Google Scholar](#) ]

39. Ure B.M., Niewold T.A., Bax N.M.A., Ham M., van de Zee D.C., Essen G.J. Peritoneal, systemic, and distant organ inflammatory responses are reduced by a laparoscopic approach and carbon dioxide vs air. *Surg. Endosc.* 2002;16:836–842. doi: 10.1007/s00464-001-9093-7. [[DOI](#) ]

[[PubMed](#)] [[Google Scholar](#) ]

40. Galganska H., Jarmuszkiewicz W., Galganski L. Carbon dioxide inhibits COVID-19-type proinflammatory responses through extracellular signal-regulated kinases 1 and 2, novel carbon dioxide sensors. *Cell. Mol. Life Sci.* 2021;78:8229–8242. doi: 10.1007/s00018-021-04005-3. [[DOI](#) ] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#) ]

41. Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. *J. Clin. Investig.* 2013;123:3664–3671. doi: 10.1172/JCI67230. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
42. Takeda D., Hasegawa T., Ueha T., Imai Y., Sakakibara A., Minoda M., Kawamoto T., Minamikawa T., Shibuya Y., Akisue T., et al. Transcutaneous carbon dioxide induces mitochondrial apoptosis and suppresses metastasis of oral squamous cell carcinoma in vivo. *PLoS ONE.* 2014;9:e100530. doi: 10.1371/journal.pone.0100530. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
43. Harada R., Kawamoto T., Ueha T., Minoda M., Toda M., Onishi Y., Fukase N., Hara H., Sakai Y., Miwa M., et al. Reoxygenation using a novel CO<sub>2</sub> therapy decreases the metastatic potential of osteosarcoma cells. *Exp. Cell Res.* 2013;319:1988–1997. doi: 10.1016/j.yexcr.2013.05.019. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
44. Onishi Y., Akisue T., Kawamoto T., Ueha T., Hara H., Toda M., Harada R., Minoda M., Morishita M., Sasaki R., et al. Transcutaneous application of CO<sub>2</sub> enhances the antitumor effect of radiation therapy in human malignant fibrous histiocytoma. *Int. J. Oncol.* 2014;45:732–738. doi: 10.3892/ijo.2014.2476. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
45. Onishi Y., Kawamoto T. Transcutaneous application of carbon dioxide (CO<sub>2</sub>) enhances chemosensitivity by reducing hypoxic conditions in human malignant fibrous histiocytoma. *J. Cancer Sci. Ther.* 2012;4:74–181. doi: 10.4172/1948-5956.1000136. [[DOI](#)] [[Google Scholar](#)]
46. Iwata E., Hasegawa T., Ueha T., Takeda D., Saito I.,

Kawamoto T., Akisue T., Sakai Y., Sasaki R., Kuroda R., et al. Transcutaneous carbon dioxide enhances the antitumor effect of radiotherapy on oral squamous cell carcinoma. *Oncol. Rep.* 2018;40:434–442. doi: 10.3892/or.2018.6444. [[DOI](#) ]

[[PubMed](#)] [[Google Scholar](#) ]

47. Hosford P.S., Wells J.A., Nizari S., Christie I.N., Theparambil S.M., Castro P.A., Hadjihambi A., Barros L.F., Ruminot I., Lythgoe M.F., et al. CO<sub>2</sub> signaling mediates neurovascular coupling in the cerebral cortex. *Nat. Commun.* 2022;13:2125. doi: 10.1038/s41467-022-29622-9. [[DOI](#) ]

[[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#) ]

48. Lahiri S., Forster R.E., 2nd CO<sub>2</sub>/H<sup>+</sup> sensing: Peripheral and central chemoreception. *Int. J. Biochem. Cell Biol.* 2003;35:1413–1435. doi: 10.1016/S1357-2725(03)00050-5.

[[DOI](#) ] [[PubMed](#)] [[Google Scholar](#) ]

49. Ogoh S., Nagaoka R., Mizuno T., Kimura S., Shidahara Y., Ishii T., Kudoh M., Iwamoto E. Acute vascular effects of carbonated warm water lower leg immersion in healthy young adults. *Physiol. Rep.* 2016;4:e13046. doi:

10.14814/phy2.13046. [[DOI](#) ] [[PMC free article](#)] [[PubMed](#)]

[[Google Scholar](#) ]

50. Minamiyama M., Yamamoto A. Direct evidence of the vasodilator action of carbon dioxide on subcutaneous microvasculature in rats by use of intra-vital video-microscopy. *J. Biorheol.* 2010;24:42–46. doi: 10.1007/s12573-010-0023-y.

[[DOI](#) ] [[Google Scholar](#) ]

51. Carr P., Graves J.E., Poston L. Carbon dioxide induced vasorelaxation in rat mesenteric small arteries precontracted with noradrenaline is endothelium dependent and mediated by nitric oxide. *Pflügers Arch.* 1993;423:343–345. doi:

10.1007/BF00374415. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

52. Bellien J., Favre J., Iacob M., Gao J., Thuillez C., Richard V., Joannidès R. Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans. *Hypertension*.

2010;55:674–680. doi:

10.1161/HYPERTENSIONAHA.109.142190. [[DOI](#)]

[[PubMed](#)] [[Google Scholar](#)]

53. Yamada M., Ishikawa T., Yamanaka A., Fujimori A., Goto K. Local neurogenic regulation of rat hindlimb circulation: CO<sub>2</sub>-induced release of calcitonin gene-related peptide from sensory nerves. *Br. J. Pharmacol.* 1997;122:710–714. doi:

10.1038/sj.bjp.0701423. [[DOI](#)] [[PMC free article](#)]

[[PubMed](#)] [[Google Scholar](#)]

54. Charter M.E., Lamb I.R., Murrant C.L. Arteriolar and capillary responses to CO<sub>2</sub> and H<sup>+</sup> in hamster skeletal muscle microvasculature: Implications for active hyperemia.

*Microcirculation*. 2018;25:e12494. doi: 10.1111/micc.12494.

[[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

55. Case R., Greenberg H., Moskowitz R. Alterations in coronary sinus pO<sub>2</sub> and O<sub>2</sub> saturation resulting from pCO<sub>2</sub> changes. *Cardiovasc. Res.* 1975;9:167–177. doi:

10.1093/cvr/9.2.167. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

56. Phillis J.W., O'Regan M.H., Song D. Further evidence for the role of adenosine in hypercapnia/acidosis-evoked coronary flow regulation. *Gen. Pharmacol.* 1999;33:431–437. doi:

10.1016/S0306-3623(99)00036-1. [[DOI](#)] [[PubMed](#)]

[[Google Scholar](#)]

57. Nees S., Gerlach E. Adenine Nucleotide and Adenosine

Metabolism in Cultured Coronary Endothelial Cells: Formation and Release of Adenine Compounds and Possible Functional Implications. In: Berne R.M., Rall T.W., Rubio R., editors. *Regulatory Function of Adenosine*. Springer; Boston, MA, USA: 1983. pp. 347–360. [[Google Scholar](#) ]

58. Dospinescu V, Nijjar S., Spanos F, Cook J., de Wolf E., Biscotti M.A., Gerdol M., Dale N. Structural determinants of CO<sub>2</sub>-sensitivity in the  $\beta$  connexin family suggested by evolutionary analysis. *Commun. Biol.* 2019;2:331. doi: 10.1038/s42003-019-0576-2. [[DOI](#) ] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#) ]

59. Hill E., Dale N., Wall M.J. CO<sub>2</sub>-sensitive connexin hemichannels in neurons and glia: Three different modes of signalling? *Int. J. Mol. Sci.* 2021;22:7254. doi: 10.3390/ijms22147254. [[DOI](#) ] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#) ]

60. Okamoto T, Akiyama M., Takeda M., Gabazza E.C., Hayashi T., Suzuki K. Connexin32 is expressed in vascular endothelial cells and participates in gap-junction intercellular communication. *Biochem. Biophys. Res. Commun.* 2009;382:264–268. doi: 10.1016/j.bbrc.2009.02.148. [[DOI](#) ] [[PubMed](#)] [[Google Scholar](#) ]

61. Braet K., Aspeslagh S., Vandamme W., Willecke K., Martin P.E.M., Evans W.H., Leybaert L. Pharmacological sensitivity of ATP release triggered by photoliberation of inositol-1,4,5-trisphosphate and zero extracellular calcium in brain endothelial cells. *J. Cell. Physiol.* 2003;197:205–213. doi: 10.1002/jcp.10365. [[DOI](#) ] [[PubMed](#)] [[Google Scholar](#) ]

62. Kirby B.S., Crecelius A.R., Richards J.C., Dinunno F.A. Sources of intravascular ATP during exercise in humans:

- Critical role for skeletal muscle perfusion. *Exp. Physiol.* 2013;98:988–998. doi: 10.1113/expphysiol.2012.071555. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
63. Brayden J.E. Functional roles of KATP channels in vascular smooth muscle. *Clin. Exp. Pharmacol. Physiol.* 2002;29:312–316. doi: 10.1046/j.1440-1681.2002.03650.x. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
64. Davies N.W. Modulation of ATP-sensitive K<sup>+</sup> channels in skeletal muscle by intracellular protons. *Nature.* 1990;343:375–377. doi: 10.1038/343375a0. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
65. Asadi A.K., Sá R.C., Arai T.J., Theilmann R.J., Hopkins S.R., Buxton R.B., Prisk G.K. Regional pulmonary perfusion patterns in humans are not significantly altered by inspiratory hypercapnia. *J. Appl. Physiol.* 2019;127:365–375. doi: 10.1152/jappphysiol.00254.2018. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
66. Baudouin S.V., Evans T.W. Action of carbon dioxide on hypoxic pulmonary vasoconstriction in the rat lung: Evidence against specific endothelium-derived relaxing factor-mediated vasodilation. *Crit Care Med.* 1993;21:740–746. doi: 10.1097/00003246-199305000-00018. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
67. Dorrington K.L., Talbot N.P. Human pulmonary vascular responses to hypoxia and hypercapnia. *Pflugers Arch.* 2004;449:1–15. doi: 10.1007/s00424-004-1296-z. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
68. Barer G.R., Shaw J.W. Pulmonary vasodilator and vasoconstrictor actions of carbon dioxide. *J. Physiol.*

- 1971;213:633–645. doi: 10.1113/jphysiol.1971.sp009405. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
69. Duling B.R. Changes in microvascular diameter and oxygen tension induced by carbon dioxide. *Circ. Res.* 1973;32:370–376. doi: 10.1161/01.RES.32.3.370. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
70. Sakai Y., Miwa M., Oe K., Ueha T., Koh A., Niikura T., Iwakura T., Lee S.Y., Tanaka M., Kurosaka M. A novel system for transcutaneous application of carbon dioxide causing an “artificial bohr effect” in the human body. *PLoS ONE.* 2011;6:e24137. doi: 10.1371/journal.pone.0024137. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
71. Bohr C., Hasselbalch K., Krogh A. Ueber einen in biologischer beziehung wichtigen einfluss, den die kohlendäurespannung des blutes auf dessen sauerstoffbindung übt1. *Skandinavisches Archiv Für Physiologie.* 1904;16:402–412. doi: 10.1111/j.1748-1716.1904.tb01382.x. [[DOI](#)] [[Google Scholar](#)]
72. Malte H., Lykkeboe G. The bohr/haldane effect: A model-based uncovering of the full extent of its impact on O<sub>2</sub> delivery to and CO<sub>2</sub> removal from tissues. *J. Appl. Physiol.* 2018;125:916–922. doi: 10.1152/jappphysiol.00140.2018. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
73. Xu Y., Elimban V., Dhalla N.S. Carbon dioxide water-bath treatment augments peripheral blood flow through the development of angiogenesis. *Can. J. Physiol. Pharmacol.* 2017;95:938–944. doi: 10.1139/cjpp-2017-0125. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
74. Ferrara N., Gerber H., LeCouter J. The biology of VEGF

and its receptors. *Nat. Med.* 2003;9:669–676. doi: 10.1038/nm0603-669. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

75. Selfridge A.C., Cavadas M.A.S., Scholz C.C., Campbell E.L., Welch L.C., Lecuona E., Colgan S.P., Barrett K.E., Sporn P.H.S., Sznajder J.I., et al. Hypercapnia suppresses the HIF-dependent adaptive response to hypoxia. *J. Biol. Chem.* 2016;291:11800–11808. doi: 10.1074/jbc.M116.713941. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

76. Takemori T., Kawamoto T., Ueha T., Toda M., Morishita M., Kamata E., Fukase N., Hara H., Fujiwara S., Niikura T., et al. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis. *Oncol. Rep.* 2018;40:2079–2087. doi: 10.3892/or.2018.6608. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

77. Coffey V.G., Jemiolo B., Edge J., Garnham A.P., Trappe S.W., Hawley J.A. Effect of consecutive repeated sprint and resistance exercise bouts on acute adaptive responses in human skeletal muscle. *Am. J. Physiol.-Regul. Integr. Comp. Physiol.* 2009;297:R1441–R1451. doi: 10.1152/ajpregu.00351.2009. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

78. Coffey V.G., Hawley J.A. Concurrent exercise training: Do opposites distract? *J. Physiol.* 2017;595:2883–2896. doi: 10.1113/JP272270. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

79. Arany Z., Foo S., Ma Y., Ruas J.L., Bommi-Reddy A., Girnun G., Cooper M., Laznik D., Chinsomboon J., Rangwala S.M., et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 $\alpha$ . *Nature.* 2008;451:1008–1012. doi: 10.1038/nature06613.

[\[DOI\]](#) ] [\[PubMed\]](#) [\[Google Scholar\]](#) ]

80. Haas T.L., Lloyd P.G., Yang H., Terjung R.L. Exercise Training and Peripheral Arterial Disease. *Compr. Physiol.* 2012;2:2933–3017. doi: 10.1002/cphy.c110065. [\[DOI\]](#) ] [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#) ]

81. Yan Z., Okutsu M., Akhtar Y.N., Lira V.A. Regulation of exercise-induced fiber type transformation, mitochondrial biogenesis, and angiogenesis in skeletal muscle. *J. Appl. Physiol.* 2011;110:264–274. doi: 10.1152/jappphysiol.00993.2010. [\[DOI\]](#) ] [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#) ]

82. Sopariwala D.H., Likhite N., Pei G., Haroon F., Lin L., Yadav V., Zhao Z., Narkar V.A. Estrogen-related receptor  $\alpha$  is involved in angiogenesis and skeletal muscle revascularization in hindlimb ischemia. *Faseb. J.* 2021;35:e21480. doi: 10.1096/fj.202001794RR. [\[DOI\]](#) ] [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#) ]

83. Zhang L., Chen L., Zhang M., Qi H., Chen L., Chen H., Zhong M., Shi X., Li Q. Downregulation of ERRA inhibits angiogenesis in human umbilical vein endothelial cells through regulating VEGF production and PI3K/akt/STAT3 signaling pathway. *Eur. J. Pharmacol.* 2015;769:167–176. doi: 10.1016/j.ejphar.2015.11.014. [\[DOI\]](#) ] [\[PubMed\]](#) [\[Google Scholar\]](#) ]

84. Likhite N., Yadav V., Milliman E.J., Sopariwala D.H., Lorca S., Narayana N.P., Sheth M., Reineke E.L., Giguère V., Narkar V. Loss of estrogen-related receptor alpha facilitates angiogenesis in endothelial cells. *Mol. Cell Biol.* 2019;39:411. doi: 10.1128/MCB.00411-18. [\[DOI\]](#) ] [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#) ]

85. Okamoto T., Akita N., Kawamoto E., Hayashi T., Suzuki K., Shimaoka M. Endothelial connexin32 enhances angiogenesis by positively regulating tube formation and cell migration. *Exp. Cell Res.* 2014;321:133–141. doi: 10.1016/j.yexcr.2013.12.002. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
86. Rahimi N. The ubiquitin-proteasome system meets angiogenesis. *Mol. Cancer Res.* 2012;11:538–548. doi: 10.1158/1535-7163.MCT-11-0555. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
87. Linthwaite V.L., Pawloski W., Pegg H.B., Townsend P.D., Thomas M.J., So V.K.H., Brown A.P., Hodgson D.R.W., Lorimer G.H., Fushman D., et al. Ubiquitin is a carbon dioxide-binding protein. *Sci. Adv.* 2021;7:eabi5507. doi: 10.1126/sciadv.abi5507. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
88. Deng M., Yang X., Qin B., Liu T., Zhang H., Guo W., Lee S., Kim J., Yuan J., Pei H., et al. Deubiquitination and activation of AMPK by USP10. *Mol. Cell.* 2016;61:614–624. doi: 10.1016/j.molcel.2016.01.010. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
89. Hardie D.G., Ross F.A., Hawley S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. *Nat. Rev. Mol. Cell Biol.* 2012;13:251–262. doi: 10.1038/nrm3311. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
90. Shoag J., Arany Z. Regulation of hypoxia-inducible genes by PGC-1 $\alpha$ . *Arterioscl. Throm. Vas.* 2010;30:662–666. doi: 10.1161/ATVBAHA.108.181636. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

91. Cummins E.P, Oliver K.M., Lenihan C.R., Fitzpatrick S.F., Bruning U., Scholz C.C., Slattery C., Leonard M.O., McLoughlin P, Taylor C.T. NF- $\kappa$ B links CO<sub>2</sub> sensing to innate immunity and inflammation in mammalian cells. *J. Immunol.* 2010;185:4439–4445. doi: 10.4049/jimmunol.1000701.

[[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

92. Keogh C.E., Scholz C.C., Rodriguez J., Selfridge A.C., von Kriegsheim A., Cummins E.P. Carbon dioxide-dependent regulation of NF-kappaB family members RelB and p100 gives molecular insight into CO<sub>2</sub>-dependent immune regulation. *J. Biol. Chem.* 2017;292:11561–11571. doi:

10.1074/jbc.M116.755090. [[DOI](#)] [[PMC free article](#)]

[[PubMed](#)] [[Google Scholar](#)]

93. Dogliotti G., Galliera E., Iorio E., De Bernardi Di Valserra M., Solimene U., Corsi M.M. Effect of immersion in CO<sub>2</sub>-enriched water on free radical release and total antioxidant status in peripheral arterial occlusive disease. *Int. Angiol.*

2011;30:12–17. [[PubMed](#)] [[Google Scholar](#)]

94. Bolevich S., Kogan A., Zivkovic V., Djuric D., Novikov A., Vorobyev S., Jakovljevic V. Protective role of carbon dioxide (CO<sub>2</sub>) in generation of reactive oxygen species. *Mol. Cell Biochem.* 2016;411:317–330. doi: 10.1007/s11010-015-2594-

9. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

95. Veselá A., Wilhelm J. The role of carbon dioxide in free radical reactions of the organism. *Physiol. Res.* 2002;51:335–

339. [[PubMed](#)] [[Google Scholar](#)]

96. Nemeth B., Kiss I., Jencsik T., Peter I., Kreska Z., Koszegi T., Miseta A., Kustan P, Boncz I., Laczó A., et al. Angiotensin-converting enzyme inhibition improves the effectiveness of transcutaneous carbon dioxide treatment. *vivo.* 2017;31:425–

428. doi: 10.21873/invivo.11077. [[DOI](#)] [[PMC free article](#)]

[[PubMed](#)] [[Google Scholar](#)]

97. Botusan I.R., Sunkari V.G., Savu O., Catrina A.I., Grünler J., Lindberg S., Pereira T., Ylä-Herttuala S., Poellinger L., Brismar K., et al. Stabilization of HIF-1 $\alpha$  is critical to improve wound healing in diabetic mice. *Proc. Nat. Acad. Sci. USA*. 2008;105:19426–19431. doi: 10.1073/pnas.0805230105.

[[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

98. Stewart K.J. Role of exercise training on cardiovascular disease in persons who have type 2 diabetes and hypertension.

*Cardiol. Clin.* 2004;22:569–586. doi:

10.1016/j.ccl.2004.06.007. [[DOI](#)] [[PubMed](#)] [[Google](#)

[Scholar](#)]

99. Maruyama K., Okada T., Ueha T., Isohashi K., Ikeda H., Kanai Y., Sasaki K., Gentsu T., Ueshima E., Sofue K., et al. In vivo evaluation of percutaneous carbon dioxide treatment for improving intratumoral hypoxia using 18F-fluoromisonidazole PET-CT. *Oncol. Lett.* 2021;21:207. doi:

10.3892/ol.2021.12468. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)]

[[Google Scholar](#)]

100. Summers B.A., Overholt J.L., Prabhakar N.R. CO<sub>2</sub> and pH independently modulate L-type Ca<sup>2+</sup> current in rabbit carotid body glomus cells. *J. Neurophysiol.* 2002;88:604–612. doi:

10.1152/jn.2002.88.2.604. [[DOI](#)] [[PubMed](#)] [[Google](#)

[Scholar](#)]

101. Vadász I., Dada L.A., Briva A., Trejo H.E., Welch L.C., Chen J., Tóth P.T., Lecuona E., Witters L.A., Schumacker P.T., et al. AMP-activated protein kinase regulates CO<sub>2</sub>-induced alveolar epithelial dysfunction in rats and human cells by promoting Na<sup>+</sup>, K<sup>+</sup>-ATPase endocytosis. *J. Clin. Investig.*

2008;118:752–762. doi: 10.1172/JCI29723. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

102. Irrcher I., Adhietty P.J., Sheehan T., Joseph A., Hood D.A. PPARgamma coactivator-1alpha expression during thyroid hormone- and contractile activity-induced mitochondrial adaptations. *Am. J. Physiol: Cell Physiol.* 2003;284:C1669–C1677. doi: 10.1152/ajpcell.00409.2002. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

103. Ojuka E.O., Jones T.E., Han D., Chen M., Holloszy J.O. Raising Ca<sup>2+</sup> in L6 myotubes mimics effects of exercise on mitochondrial biogenesis in muscle. *FASEB J.* 2003;17:675–681. doi: 10.1096/fj.02-0951com. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

104. Montalto A.S., Currò M., Russo T., Visalli G., Impellizzeri P., Antonuccio P., Arena S., Borruto F.A., Scalfari G., Ientile R., et al. In Vitro CO<sub>2</sub>-induced ROS production impairs cell cycle in SH-SY5Y neuroblastoma cells. *Pediatr. Surg. Int.* 2013;29:51–59. doi: 10.1007/s00383-012-3206-3. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

105. Iwabu M., Yamauchi T., Okada-Iwabu M., Sato K., Nakagawa T., Funata M., Yamaguchi M., Namiki S., Nakayama R., Tabata M., et al. Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca<sup>2+</sup> and AMPK/SIRT1. *Nature.* 2010;464:1313–1319. doi: 10.1038/nature08991. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

## Associated Data

---

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

## Data Availability Statement

All data reported is publicly available.

---

Articles from International Journal of Molecular Sciences are provided here courtesy of **Multidisciplinary Digital Publishing Institute (MDPI)**